White label is typically the faster and lower-risk route for first-time supplement brands in Southeast Asia, while custom formulation offers deeper differentiation but requires greater capital, longer timelines, and more complex regulatory navigation. The right choice depends less on ambition and more on sequencing—how founders balance speed, validation, and long-term brand defensibility.
Understanding white label vs custom formulation in Southeast Asia
White label and custom formulation serve fundamentally different strategic purposes.
White label manufacturing uses pre-developed, standardized formulations that brands can repackage under their own identity. These products are typically already stability-tested and aligned with common regulatory requirements, allowing faster commercialization.
Custom formulation, by contrast, involves developing a unique product from the ground up—defining ingredients, dosages, delivery formats, and functional positioning. This approach enables exclusivity but introduces additional layers of R&D, sourcing, and regulatory work.
In Southeast Asia, this decision carries additional weight due to market fragmentation. While ASEAN has introduced harmonization frameworks for health supplements, individual countries—including Thailand, Indonesia, Vietnam, Malaysia, and the Philippines—maintain distinct regulatory processes, documentation requirements, and approval timelines.
For founders entering multiple markets, the choice between white label and custom formulation becomes less about product preference and more about operational feasibility. Speed to market, capital exposure, regulatory complexity, and differentiation must be evaluated together rather than in isolation.
Speed to market: the reality of launch timelines in Southeast Asia
For first-time brands, speed is often the most critical constraint. Early-stage companies need to validate demand, pricing, and channel strategy before committing significant capital.
White label products offer a clear advantage here. Because formulations are already developed and tested, the primary workstreams include:
- Branding and packaging design
- Claims alignment with local regulations
- Product registration or notification
This significantly compresses the pre-launch timeline.
Custom formulation introduces multiple additional phases:
- Concept development and feasibility assessment
- Ingredient sourcing and compatibility testing
- Prototype development and pilot runs
- Stability testing and documentation preparation
Only after these steps can regulatory submission begin.
In Southeast Asia, regulatory timelines vary by country and product classification but often extend over several months. Some markets operate notification-based systems for lower-risk supplements, while others require full pre-market approval with supporting safety and quality documentation. Additional requirements—such as Halal certification in Indonesia or specific labeling standards in Malaysia—can further extend timelines.
For early-stage brands, these overlapping timelines can delay revenue generation and increase burn rate. As a result, white label is often used as a speed-to-validation tool, allowing brands to enter the market quickly, test positioning, and iterate before committing to more complex product development.
Differentiation: how much uniqueness is actually required early on
Custom formulation is often associated with stronger differentiation, but the strategic importance of differentiation depends on the brand’s stage.
With custom development, brands can:
- Control ingredient selection and dosage levels
- Incorporate branded or clinically studied actives
- Design unique delivery systems (e.g., gummies, sachets, effervescents)
- Build proprietary positioning that is harder to replicate
This supports premium pricing and long-term brand equity.
However, differentiation at the formulation level is not always the primary driver of early success—especially in Southeast Asia. In many markets, consumer trust is shaped by:
- Certifications (e.g., Halal, GMP)
- Brand credibility and storytelling
- Clear, compliant benefit communication
- Localization of claims and positioning
This creates an important insight: early-stage differentiation is often commercial rather than technical.
White label products, while standardized, still allow brands to differentiate through:
- Packaging design and format
- Flavor and user experience
- Market-specific positioning
- Channel strategy (e.g., e-commerce vs pharmacy)
A common and effective strategy is phased differentiation:
- Phase 1: Launch with white label to validate demand
- Phase 2: Introduce custom formulations based on proven insights
- Phase 3: Expand into proprietary or flagship SKUs
This approach allows brands to avoid over-investing in differentiation before product-market fit is established.
MOQ and capital: managing inventory risk and cash flow
Minimum order quantity (MOQ) is one of the most practical constraints for first-time founders.
White label manufacturing typically offers lower MOQs because production is aggregated across multiple brands using the same formulation. In some cases, manufacturers may offer entry points in the low hundreds to low thousands of units, depending on the dosage form and packaging format.
Custom formulation, on the other hand, requires dedicated production runs. This often results in higher MOQs, particularly for formats such as softgels, gummies, or specialized delivery systems, where production efficiency depends on scale.
The implications are significant:
White label:
- Lower upfront inventory investment
- Reduced risk of unsold or expiring stock
- Greater flexibility to test multiple SKUs or variants
Custom formulation:
- Higher capital tied up in inventory
- Increased exposure to demand uncertainty
- Lower unit costs at scale (once demand is proven)
For founders operating with limited capital, MOQ is not just a procurement detail—it directly affects:
- Cash flow
- Marketing budget allocation
- Ability to iterate quickly
In practice, many Southeast Asian startups prioritize capital efficiency in their first 12–18 months. White label enables this by minimizing inventory risk while freeing up resources for customer acquisition and distribution.
Regulatory complexity across Southeast Asia
Regulation is one of the most underestimated challenges in launching supplement brands in Southeast Asia.
Although ASEAN has developed guidelines to harmonize aspects of supplement regulation, implementation remains country-specific. Each market maintains its own authority and processes, including:
- Thailand FDA
- Indonesia’s BPOM
- Malaysia’s NPRA
- Philippines FDA
- Vietnam’s Ministry of Health
Key differences across markets include:
- Pre-market approval vs notification systems
- Required technical documentation and safety data
- Permitted ingredients and dosage limits
- Labeling and claims restrictions
- Certification requirements (e.g., Halal)
For brands entering multiple markets, this creates a fragmented regulatory landscape that requires careful planning.
How white label affects regulatory execution
White label does not eliminate regulatory requirements, but it can streamline execution:
- Manufacturers may already have technical dossiers, stability data, and quality documentation prepared
- Existing formulations are often aligned with commonly accepted ingredient lists
- Documentation can be adapted more efficiently for multiple markets
How custom formulation increases complexity
Custom products require:
- Full documentation for new formulations
- Additional safety and stability validation
- Potential reformulation if ingredients are restricted in specific markets
Regulators across the region are also increasing scrutiny on:
- Product claims
- Label accuracy
- Ingredient safety
Scientific literature on dietary supplement regulation emphasizes the importance of robust quality systems and accurate labeling, which are increasingly enforced across emerging markets. For first-time brands, this makes partner selection critical—an experienced OEM can significantly reduce compliance risk.
Strategic tradeoffs for first-time Southeast Asian brands
The decision between white label and custom formulation is best understood as a tradeoff between speed-to-validation and long-term defensibility.
White label advantages:
- Faster market entry
- Lower MOQs and capital requirements
- Simplified documentation workflows
- Reduced R&D investment
White label limitations:
- Limited formulation-level differentiation
- Potential margin pressure in competitive categories
- Less control over product uniqueness
Custom formulation advantages:
- Unique positioning and ingredient control
- Potential for stronger brand equity
- Better alignment with premium or clinical positioning
Custom formulation limitations:
- Longer development timelines
- Higher MOQs and upfront investment
- More complex regulatory requirements
For most first-time brands in Southeast Asia, this is not a binary decision. It is a sequencing strategy that evolves with the business.
Tradeoff summary for first-time brands
| Factor | White label supplements | Custom formulation supplements |
| Time to market | Fast, leveraging existing formulations and documentation | Slower, requiring development, testing, and full regulatory submission |
| Differentiation | Limited to branding, positioning, and packaging | High, with control over ingredients and formulation design |
| MOQ and capital | Lower MOQs, lower inventory risk, higher unit cost | Higher MOQs, higher capital requirement, better unit economics at scale |
| Regulatory complexity | Streamlined documentation preparation | Full regulatory burden for new formulations |
| Ideal stage | Validation and early market entry | Scaling, premium positioning, and brand expansion |
A practical decision framework for founders
Rather than asking which option is “better,” founders should evaluate their constraints across four dimensions:
1. Time
- Do you need to launch within 3–6 months?
→ White label is typically more viable
2. Capital
- Can you absorb higher inventory and development costs?
→ If not, prioritize white label
3. Differentiation strategy
- Is your brand built on a strong scientific or clinical concept?
→ Custom formulation may be justified earlier
4. Regulatory capability
- Do you have access to regulatory expertise across multiple markets?
→ If not, reduce complexity through standardized formulations
Decision shortcut:
- Choose white label if your priority is speed, validation, and capital efficiency
- Choose custom formulation if your priority is defensibility, uniqueness, and long-term positioning
How NuWave supports both pathways in Southeast Asia
For first-time brands, execution matters as much as strategy. The complexity of Southeast Asia—across regulatory systems, consumer preferences, and supply chains—makes partner selection a critical success factor.
NuWave supports both white label and custom formulation pathways, allowing brands to align their product strategy with their stage of growth.
For early-stage companies, white label programs enable faster launches with lower MOQs and streamlined documentation. As brands scale, custom formulation services allow for the development of proprietary products that strengthen differentiation and margin structure.
With experience across Southeast Asian markets, NuWave can also support:
- Regulatory documentation and compliance alignment
- Market-specific claim and labeling considerations
- Product format selection based on regional demand
- Transition planning from white label to custom SKUs
This dual capability enables founders to move from validation to scale without switching partners or restarting operational processes.
If you are evaluating white label vs custom formulation for your first supplement brand, working with a partner that understands both pathways—and the realities of Southeast Asian markets—can significantly reduce risk and accelerate execution. Explore your options with NuWave.
References
National Center for Biotechnology Information. (2019). Regulation of dietary supplements: Overview of global approaches. PubMed Central. https://pmc.ncbi.nlm.nih.gov/articles/PMC6513729/
ASEAN Secretariat. (2015). ASEAN guidelines on health supplements. https://asean.org/book/asean-guidelines-on-health-supplements/
Food and Drug Administration Thailand. (n.d.). Guidelines for health product registration. https://www.fda.moph.go.th
Indonesian National Agency of Drug and Food Control (BPOM). (n.d.). Regulation of health supplements in Indonesia. https://www.pom.go.id
Ministry of Health Vietnam. (n.d.). Regulations on food supplements and health products. https://moh.gov.vn
National Pharmaceutical Regulatory Agency Malaysia. (n.d.). Guidelines for health supplements. https://npra.gov.my
Philippine Food and Drug Administration. (n.d.). Guidelines on food supplements registration. https://www.fda.gov.ph
Euromonitor International. (2024). Vitamins and dietary supplements in Asia Pacific. https://www.euromonitor.com
McKinsey & Company. (2023). The rise of health and wellness in Asia: Implications for consumer brands. https://www.mckinsey.com
Statista. (2024). Dietary supplements market in Southeast Asia. https://www.statista.com
Leave a Reply